Last reviewed · How we verify
Ligustrazine by intravenously administration
Ligustrazine inhibits platelet aggregation and improves microcirculation by reducing blood viscosity and enhancing blood flow.
Ligustrazine inhibits platelet aggregation and improves microcirculation by reducing blood viscosity and enhancing blood flow. Used for Acute ischemic stroke, Cerebral infarction, Peripheral vascular disease.
At a glance
| Generic name | Ligustrazine by intravenously administration |
|---|---|
| Also known as | Tetramethylpyrazine by intravenously administration |
| Sponsor | Shenzhen Kangning Hospital |
| Drug class | Antiplatelet agent / Vasodilator |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ligustrazine (tetramethylpyrazine) is an alkaloid derived from Ligusticum wallichii that works primarily as an antiplatelet and vasodilatory agent. It reduces platelet aggregation, decreases blood viscosity, and improves microcirculatory blood flow, making it useful in conditions characterized by poor circulation and thrombotic risk. The drug also has antioxidant properties that may contribute to its therapeutic effects.
Approved indications
- Acute ischemic stroke
- Cerebral infarction
- Peripheral vascular disease
- Diabetic angiopathy
Common side effects
- Dizziness
- Headache
- Gastrointestinal discomfort
- Bleeding risk (minor)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: